76 results
This table provide an overview of prices contracted with suppliers by UNICEF per vaccine.
This document summarizes current technical and programmatic information on WHO prequalified PCV
products to facilitate informed country choices for PCV introduction or product switch for...
VIEW-hub is an open-access data visualization tool that displays data on vaccine introduction, use, coverage, access, impact, and disease burden for nine vaccines, including the pneumococcal...
Pneumococcal conjugate vaccine (PCV) catch-up vaccination at the time of PCV introduction in children aged 12 to 59 months of age has been recommended by WHO as reflected in the 2019 WHO position...
Narendra Arora, INCLEN; Naor Bar-Zeev, WHO; Rudzani Muloiwa, U. Cape Town; Deborah Watson-Jones, LSHTM
VIEW-hub is an easy to use repository for the most relevant and recent vaccine data, covering topics such as Vaccine Introduction & Use, Immunization Equity, Vaccine Preventable Disease Burden, and...
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
This document is includes information on WHO position on pneumococcal vaccines in infants in children; vaccine characteristics; safety; PCV performance; programmatic considerations; cost and...
COSTVAC is an Excel-based toolkit that provides structured guidance on how to estimate the cost of routine immunization from a sample of health facilities and administrative levels of the health...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
UNIVAC is a single universal vaccine impact and cost-effectiveness decision support model with a standardized, accessible Excel-based (now based in R), interface and a familiar set of input steps and...
The Consortium aims to deliver a more sustainable, efficent, and transparent approach to generating disease burden and vaccine impact estimates. It works on aggregating the estimates across a...
Il s’agit d’un outil simple dans Excel qui permet d’évaluer et de comparer les coûts des programmes de vaccination VPC (vaccin pneumococcique conjugué) sur un an et sur une période totale...
Narendra Arora (INCLEN), David Durrheim (University of Newcastle), Pradeep Haldar (MOHFW, India), Keith Klugman (BMGF), Kate O’Brien (International Vaccine Access Center), Collins Tabu (Ministry of...
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
PATH's Pneumococcal Conjugate Vaccine Cost Calculator is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) programs annually and for a period of 10...
Summary guidance for national authorities and immunization programme managers for the switch from GlaxoSmithKline Biologicals SA Synflorix® (PCV 10) to Pfizer Prevenar13® vaccine (PCV 13)
Based on current timelines, PCV13 4-dose vials have become available to Gavi countries in 2017 and PCV10 4-dose vials are forecasted to become available in 2018. The availability of PCV10 4-dose...
This table displays the characteristics of different presentations of Pneumococcal Conjugate Vaccines
Background: Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines....
Each year, IVAC prepares the Pneumonia and Diarrhea Progress Report and publishes it for World Pneumonia Day on November 12. The report evaluates the annual progress made in prevention and control of...
Background: In Quebec, 7-valent (PCV7), 10-valent (PCV10) and 13-valent (PCV13) pneumococcal conjugate vaccines were successively used for the immunization of children according to a 2+1 doses...
Each year, IVAC prepares the Pneumonia and Diarrhea Progress Report and publishes it for World Pneumonia Day on November 12. The report evaluates the annual progress made in prevention and control of...
Streptococcus pneumoniae (pneumococcus) is responsible for serious pediatric respiratory infections, and kills close to one million children under the age of five each year. Unfortunately, the...
Background: Streptococcus pneumoniae is a leading cause of vaccine-preventable disease in children under 5 years. Immunocompromised children and those with underlying diseases are at increased risk...
Pneumococcal conjugate vaccines have proven highly effective in decreasing invasive disease and pneumonia in young children. However, there is considerable geographic variability in the impact of...
To address the epidemiologic and diagnostic complexity of pneumococcal disease in particular, and to support our partners in their technical evaluations of pneumococcal disease and vaccines, we are...
IVAC is releasing a set of tools capturing and synthesizing the latest and best available data around pneumococcal diseases and vaccines with technical decision-makers in mind. We have developed a...
The global analysis, entitled Gap Analyses of PCV Impact Evaluations in Settings of Routine Use, is the output of an IVAC-maintained database of completed and ongoing vaccine impact studies for these...
BACKGROUND: Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2,...
On Oct 10, 2015, Médecins Sans Frontières (MSF) rejected Pfizer\'s proposed donation of 1 million doses of its branded pneumococcal conjugate vaccine (PCV).1 The news caused a stir in the global...
BACKGROUND The recently launched Pneumo Rischio eHealth project, which consists of an app, a website, and social networking activity, is aimed at increasing public awareness of invasive pneumococcal...
Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing...
Abstract
Background
In a previous study, Chinese infants were vaccinated with 7-valent pneumococcal conjugate vaccine (PCV7) ⩾7 days before routine diphtheria, tetanus, and acellular pertussis...
Abstract
Streptococcus pneumoniae is the leading cause of bacterial pneumonia, meningitis and sepsis in children worldwide. Despite available evidence on pneumococcal conjugate vaccine (PCV) impact...
BACKGROUND:
Mortality due to severe pneumonia during childhood in resource-constrained settings is high, but data to provide basis for interventions to improve survival are limited. The objective of...
Background: Pneumonia and pneumococcal disease cause a large disease burden in resource-constrained settings. We pursue an extended cost-effectiveness analysis (ECEA) of two fully publicly financed...
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in...
Pneumococcal disease is the leading cause of vaccine-preventable death in children younger than 5 years of age worldwide. The World Health Organization recommends pneumococcal conjugate vaccine as a...
The goal of this Geographic Information System (GIS) study was to obtain accurate information on the locations of study subjects, road network and services for research purposes so that the clinical...
BACKGROUND:
A recently developed 10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) is expected to afford protection against more than two thirds of isolates...
With the accelerated introduction of new vaccines in low-income settings, understanding immunization program performance is critical. We sought to improve immunization history acquisition from...
ntroduction of the 7-valent pneumococcal conjugate vaccine (PCV7) into the childhood immunization schedule was associated with substantial reductions in invasive pneumococcal disease (IPD) and...
Advocacy, policy, research and intervention efforts against childhood pneumonia have lagged behind other health issues, including malaria, measles and tuberculosis. Accelerating progress on the issue...